Every Form 4 that BIO-key International, Inc. (BKYI) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BKYI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BKYI filings page.
BIO-key International’s Chief Legal Officer, James David Sullivan, acquired 250 shares of Common Stock as a grant under the company’s 2021 Employee Stock Purchase Plan. The shares were credited at a price of $3.83 per share in a transaction classified as a grant or award.
After this transaction, Sullivan directly holds 9,986 shares of BIO-key common stock. The footnotes note that all share amounts reflect BIO-key’s 1-for-10 reverse stock split that became effective on April 30, 2026.
BIO-key International Chief Executive Officer and Chairman Michael W. DePasquale acquired 250 shares of common stock at $3.83 per share. These shares were obtained under the BIO-key International, Inc. 2021 Employee Stock Purchase Plan, as amended, in a transaction exempt under Rule 16b-3(d) and Rule 16b-3(c). After this grant-related acquisition, his directly held common stock position increased to 10,778 shares. All reported share amounts reflect BIO-key’s 1-for-10 reverse stock split effective April 30, 2026.
BIO-key International Chief Technology Officer Mira K. Lacous acquired 250 shares of common stock at $3.83 per share through the company’s 2021 Employee Stock Purchase Plan. After this award, she directly holds 4,076 shares. All share amounts reflect a 1-for-10 reverse stock split effective April 30, 2026.